Scepticism in press over Kintor’s COVID-19 US drug trial
pharmaphorum
MAY 14, 2021
China’s Kintor Pharmaceutical has begun late-stage US clinical development of its potential COVID drug proxalutamide – but there is scepticism over the company’s claims about its research. Reuters quoted Kintor’s chief financial officer Lucy Lu, who said that Kayali was one of its trial investigators.
Let's personalize your content